These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
489 related articles for article (PubMed ID: 33138665)
1. Practical recommendations for the management of treatment-resistant depression with esketamine nasal spray therapy: Basic science, evidence-based knowledge and expert guidance. Kasper S; Cubała WJ; Fagiolini A; Ramos-Quiroga JA; Souery D; Young AH World J Biol Psychiatry; 2021 Jul; 22(6):468-482. PubMed ID: 33138665 [TBL] [Abstract][Full Text] [Related]
2. Efficacy of Esketamine Nasal Spray Plus Oral Antidepressant Treatment for Relapse Prevention in Patients With Treatment-Resistant Depression: A Randomized Clinical Trial. Daly EJ; Trivedi MH; Janik A; Li H; Zhang Y; Li X; Lane R; Lim P; Duca AR; Hough D; Thase ME; Zajecka J; Winokur A; Divacka I; Fagiolini A; Cubala WJ; Bitter I; Blier P; Shelton RC; Molero P; Manji H; Drevets WC; Singh JB JAMA Psychiatry; 2019 Sep; 76(9):893-903. PubMed ID: 31166571 [TBL] [Abstract][Full Text] [Related]
3. Efficacy and safety of fixed doses of intranasal Esketamine as an add-on therapy to Oral antidepressants in Japanese patients with treatment-resistant depression: a phase 2b randomized clinical study. Takahashi N; Yamada A; Shiraishi A; Shimizu H; Goto R; Tominaga Y BMC Psychiatry; 2021 Oct; 21(1):526. PubMed ID: 34696742 [TBL] [Abstract][Full Text] [Related]
4. Efficacy and Safety of Flexibly Dosed Esketamine Nasal Spray Combined With a Newly Initiated Oral Antidepressant in Treatment-Resistant Depression: A Randomized Double-Blind Active-Controlled Study. Popova V; Daly EJ; Trivedi M; Cooper K; Lane R; Lim P; Mazzucco C; Hough D; Thase ME; Shelton RC; Molero P; Vieta E; Bajbouj M; Manji H; Drevets WC; Singh JB Am J Psychiatry; 2019 Jun; 176(6):428-438. PubMed ID: 31109201 [TBL] [Abstract][Full Text] [Related]
5. Treatment Response of Add-On Esketamine Nasal Spray in Resistant Major Depression in Relation to Add-On Second-Generation Antipsychotic Treatment. Dold M; Bartova L; Kasper S Int J Neuropsychopharmacol; 2020 Jul; 23(7):440-445. PubMed ID: 32570275 [TBL] [Abstract][Full Text] [Related]
6. Access and real-world use patterns of esketamine nasal spray among patients with treatment-resistant depression covered by private or public insurance. Teeple A; Zhdanava M; Pilon D; Caron-Lapointe G; Lefebvre P; Joshi K Curr Med Res Opin; 2023 Aug; 39(8):1167-1174. PubMed ID: 37492015 [TBL] [Abstract][Full Text] [Related]
7. Effect of Esketamine Nasal Spray on Olfactory Function and Nasal Tolerability in Patients with Treatment-Resistant Depression: Results from Four Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase III Studies. Doty RL; Popova V; Wylie C; Fedgchin M; Daly E; Janik A; Ochs-Ross R; Lane R; Lim P; Cooper K; Melkote R; Jamieson C; Singh J; Drevets WC CNS Drugs; 2021 Jul; 35(7):781-794. PubMed ID: 34235612 [TBL] [Abstract][Full Text] [Related]
8. Esketamine nasal spray in patients with treatment-resistant depression: the real-world experience in the French cohort early-access programme. Samalin L; Rothärmel M; Mekaoui L; Gaudré-Wattinne E; Codet MA; Bouju S; Sauvaget A Int J Psychiatry Clin Pract; 2022 Nov; 26(4):352-362. PubMed ID: 35174754 [TBL] [Abstract][Full Text] [Related]
9. Characteristics of Real-world Commercially Insured Patients With Treatment-resistant Depression Initiated on Esketamine Nasal Spray or Conventional Therapies in the United States. Karkare S; Zhdanava M; Pilon D; Nash AI; Morrison L; Shah A; Lefebvre P; Joshi K Clin Ther; 2022 Nov; 44(11):1432-1448. PubMed ID: 36207167 [TBL] [Abstract][Full Text] [Related]
10. Long-term remission following esketamine nasal spray sessions in a patient with severe and highly treatment-resistant depression: a single-case report. Arrighi L; Maakaron E; Korchia T; Lançon C; Richieri R Int Clin Psychopharmacol; 2024 Sep; 39(5):323-325. PubMed ID: 37551607 [TBL] [Abstract][Full Text] [Related]
11. Meaningful Change in Depression Symptoms Assessed with the Patient Health Questionnaire (PHQ-9) and Montgomery-Åsberg Depression Rating Scale (MADRS) Among Patients with Treatment Resistant Depression in Two, Randomized, Double-blind, Active-controlled Trials of Esketamine Nasal Spray Combined With a New Oral Antidepressant. Hudgens S; Floden L; Blackowicz M; Jamieson C; Popova V; Fedgchin M; Drevets WC; Cooper K; Lane R; Singh J J Affect Disord; 2021 Feb; 281():767-775. PubMed ID: 33261932 [TBL] [Abstract][Full Text] [Related]
12. Esketamine Nasal Spray Plus Oral Antidepressant in Patients With Treatment-Resistant Depression: Assessment of Long-Term Safety in a Phase 3, Open-Label Study (SUSTAIN-2). Wajs E; Aluisio L; Holder R; Daly EJ; Lane R; Lim P; George JE; Morrison RL; Sanacora G; Young AH; Kasper S; Sulaiman AH; Li CT; Paik JW; Manji H; Hough D; Grunfeld J; Jeon HJ; Wilkinson ST; Drevets WC; Singh JB J Clin Psychiatry; 2020 Apr; 81(3):. PubMed ID: 32316080 [TBL] [Abstract][Full Text] [Related]
13. Esketamine nasal spray for major depressive disorder with acute suicidal ideation or behavior: description of treatment access, utilization, and claims-based outcomes in the United States. Zhdanava M; Teeple A; Pilon D; Shah A; Caron-Lapointe G; Joshi K J Med Econ; 2023; 26(1):691-700. PubMed ID: 37130075 [TBL] [Abstract][Full Text] [Related]
17. Esketamine Nasal Spray versus Quetiapine for Treatment-Resistant Depression. Reif A; Bitter I; Buyze J; Cebulla K; Frey R; Fu DJ; Ito T; Kambarov Y; Llorca PM; Oliveira-Maia AJ; Messer T; Mulhern-Haughey S; Rive B; von Holt C; Young AH; Godinov Y; N Engl J Med; 2023 Oct; 389(14):1298-1309. PubMed ID: 37792613 [TBL] [Abstract][Full Text] [Related]
18. Treating bipolar depression with esketamine: Safety and effectiveness data from a naturalistic multicentric study on esketamine in bipolar versus unipolar treatment-resistant depression. Martinotti G; Dell'Osso B; Di Lorenzo G; Maina G; Bertolino A; Clerici M; Barlati S; Rosso G; Di Nicola M; Marcatili M; d'Andrea G; Cavallotto C; Chiappini S; De Filippis S; Nicolò G; De Fazio P; Andriola I; Zanardi R; Nucifora D; Di Mauro S; Bassetti R; Pettorruso M; McIntyre RS; Sensi SL; di Giannantonio M; Vita A; Bipolar Disord; 2023 May; 25(3):233-244. PubMed ID: 36636839 [TBL] [Abstract][Full Text] [Related]
19. Treatment Response With Esketamine Nasal Spray Plus an Oral Antidepressant in Patients With Treatment-Resistant Depression Without Evidence of Early Response: A Pooled Post Hoc Analysis of the TRANSFORM Studies. Turkoz I; Daly E; Singh J; Lin X; Tymofyeyev Y; Williamson D; Salvadore G; Nash AI; Macaluso M; Wilkinson ST; Nelson JC J Clin Psychiatry; 2021 Jul; 82(4):. PubMed ID: 34288609 [No Abstract] [Full Text] [Related]
20. Rethinking ketamine and esketamine action: Are they antidepressants with mood-stabilizing properties? d'Andrea G; Pettorruso M; Lorenzo GD; Mancusi G; McIntyre RS; Martinotti G Eur Neuropsychopharmacol; 2023 May; 70():49-55. PubMed ID: 36867895 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]